Regression of advanced refractory ovarian cancer treated with iodine- 131-labeled anti-CEA monoclonal antibody

Journal of Nuclear Medicine

Volumn 38, Issue 2, 1997, Pages 257-260

  Juweid, Malik ^b   Sharkey, Robert M ^b   Alavi, Abass ^b   Swayne, Lawrence C ^b   Herskovic, Thomas ^b   Hanley, Debra ^b   Rubin, Arnold D ^b   Pereira, Michael ^b   Goldenberg, David M ^a  

^a GARDEN STATE CANCER CENTER   (United States)

^b NONE

Author keywords

iodine 131 labeled anti CEA monoclonal antibody; ovarian cancer; radioimmunotherapy

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; IODINE 131; PACLITAXEL;

ADVANCED CANCER; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG RESPONSE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; CA-125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DEOXYGLUCOSE; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; OVARIAN NEOPLASMS; RADIOIMMUNOTHERAPY; REMISSION INDUCTION; SALVAGE THERAPY; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0031047095     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Wingo PA, Tong T, Bolden S. Cancer statistics. CA Cancer J Clin 1995;45:8-30.
2. Young RC, Perez CA, Hoskin WJ. Cancer of the ovary. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Principles and practice of oncology. Philadelphia, PA: JB Lippincott; 1989:1226-1263.
3. Di Saia PJ, Morrow CP, Haverback BJ, et al. Carcinoembryonic antigen in cancer of the female reproductive system. Serial plasma values correlated with disease state. Cancer 1977;39:2365-2370.
4. Van Nagell JR, Kim E, Casper S, et al. Radioimmunodetection of primary and metastatic ovarian cancer using radiolabeled antibodies to carcinoembryonic antigen. Cancer Res 1990;40:502-506.
5. Martin MW, Halpern SE. Carcinoembryonic antigen production, secretion and kinetics in BALB/c mice and a nude mouse-human tumor model. Cancer Res 1984;44:5475-5481.
6. Sharkey RM, Juweid M, Shevitz J, et al. Evaluation of a CDR-grafted (humanized) anti-carcinoembryonic antigen (CEA) monoclonal antibody in preclinical and clinical studies. Cancer Res 1995;55:5935s-5945s.
7. Primus FJ, Kelley EA, Hansen HJ, et al. "Sandwich"-type immunoassay for carcino-embryonic antigen in patients receiving murine monoclonal antibodies for diagnosis and therapy. Clin Chem 1988;34:261-264.
8. Hansen HJ, La Fontaine G, Newman ES, et al. Solving the problem of antibody interference in commercial "sandwich"-type immunoassays of carcinoembryonic antigen. Clin Chem 1989;35:146-151.
9. Courtenay-Luck NS, Epenetos AA, Sivolapenko GB, et al. Development of anti-idiotypic antibodies against tumor antigens and autoantigens in ovarian cancer patients treated intraperitoneally with mouse monoclonal antibodies. Lancet 1988;ii:894-897.
10. Kosmas C, Epenetos AA, Courtenay-Luck NS. Patients receiving murine monoclonal antibody therapy develop T cells that proliferate in vitro in response to these antibodies as antigens. Br J Cancer 1991;64:494-500.
11. Bast RC, Berek JS, Obrist R, et al. Intraperitoneal immunotherapy of human ovarian carcinoma with corynebacterium parvum. Cancer Res 1983;43:1365-1401.
12. Baum RP, Niesen A, Herte IA, et al. Activating anti-idiotypic human antimouse antibodies for immunotherapy of ovarian carcinoma. Cancer 1994;73(suppl):1121-1125.
13. Wagner U, Oehr P, Reinberg J. Immunotherapy of advanced ovarian carcinomas by activation of the idiotypic network. Biotechnol Ther 1992;3:81-89.